ESNT vs GNW: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ESNT and GNW share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ESNT and GNW exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Essent Group Ltd (NYSE: ESNT) is a Bermuda-domiciled holding company whose main subsidiary, Essent Guaranty, writes private mortgage insurance in the United States. Private mortgage insurance covers the lender (and ultimately Fannie Mae or Freddie Mac) against loss when a borrower who put down less than 20% stops paying, which is what lets a first-time buyer close with 3% to 5% down. Essent earns a small annual premium on each insured loan and keeps earning it until the borrower refinances, sells, or builds enough equity to cancel coverage. Insurance in force was about $247.9 billion at the end of March 2026, with a weighted average FICO of 747 and persistency of 84.7%, meaning the vast majority of the book renews each year. Two smaller arms sit alongside it: Essent Re, a Bermuda reinsurer that takes GSE credit risk transfer and, more recently, third-party property and casualty business including a Lloyd's program, and Essent Title Insurance (the former Agents National Title, bought from CoreLogic in 2023) with the Boston National Title agency.

Full ESNT guide

Genworth Financial, based in Richmond, Virginia, is what is left of a much larger insurer after two decades of restructuring. It reports three main pieces. Enact is a private mortgage insurance business that Genworth took public in 2021 and still owns roughly 81% of, and it produces essentially all of the group's operating earnings. The Long-Term Care Insurance segment is a closed block: policies written largely between the 1970s and the 2000s, no longer sold, whose claims and reserves Genworth manages down over decades. A smaller Life and Annuities segment is also in runoff. The newer effort is CareScout, which builds a quality-assured network of home care and senior living providers, earns fees on placements and preferred pricing, and through CareScout Insurance is writing fresh long-term care coverage on modern assumptions. Trailing twelve-month revenue is ~$7.4 billion against a market capitalisation of ~$3.84 billion at ~$10.16 per share.

Full GNW guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ESNT drivers: Insurance in force and persistency; Credit performance and reserve development.
• GNW drivers: Enact cash flow and the holding company discount; The multi-year rate action plan on legacy long-term care.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Essent's core exposure is the housing and employment cycle, and the current low loss ratio assumes home equity keeps converting would-be claims into sales. For GNW, the core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ESNT if you believe its drivers more; GNW if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ESNT and GNW guides.

ESNT. Essent carried a market capitalization near $6.1 billion on roughly 92 million shares in early August 2026, putting the stock at about 9 to 10 times trailing earnings and a modest premium to its $61.20 book value per share. Q1 2026 net income was $171.8 million, or $1.82 per diluted share, on revenue of $336.1 million, with an annualized return on average equity of 12.0%. Second-quarter results were scheduled for August 7, 2026, so figures here reflect the March quarter. Valuation numbers are approximate and move with the share price.

GNW. Figures are approximate and tied to the asOf date; check live numbers before acting. Standard earnings multiples do little work here, because GAAP results consolidate all of Enact while charging the full drag of the long-term care closed block, and reported equity of ~$8.7 billion at June 30, 2026 includes the minority interest in Enact and swings with accumulated other comprehensive income. Most analysis of GNW is sum-of-the-parts instead: the market value of the Enact stake, less holding company debt and corporate costs, less whatever haircut the long-term care block deserves.

Headline figures (approximate, August 2026): ESNT shows net premiums earned (q1 2026) ~$260M, net income (ttm) ~$686M, diluted eps (ttm) ~$7.03, book value per share ~$61 (Mar 31, 2026); GNW shows revenue (ttm) ~$7.4 billion, market cap ~$3.84 billion (~$10.16 per share), enact stake ~81% of Enact Holdings (ACT), worth ~$5.5 billion at Enact's ~$6.9 billion market value, adjusted operating income ex-closed block (q2 2026) ~$112 million, or ~$0.29 per diluted share.

ESNT and GNW are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ESNT and GNW exposure against your real portfolio. It is not an investment adviser.